68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
Status:
Completed
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
68Ga-labelled [DOTA0,DGlu1,desGlu2-6,(N-Me)Nle11,1-Nal13]minigastrin (68Ga-DOTA-MGS5) is a
novel radiopharmaceutical for intravenous administration for evaluation of the
cholecystokinin receptor (CCK2R) status in patients with CCK2R-related malignancies. CCK2R is
expressed at high incidence in medullary thyroid carcinomas (92%) and frequently expressed
also in gastroenteropancreatic neuroendocrine tumours (GEP-NET, 22%). In this phase I/IIa
study the safety of administration and the biodistribution of 68Ga-DOTA-MGS5 will be
evaluated in patients with advanced MTC as well as gastroenteropancreatic and
bronchopulmonary NET. In addition, the visualization of tumour lesions as well as the
absorbed organ and tumour radiation dose will be evaluated. The new positron emission
tomography (PET) imaging modality has the potential to improve the diagnostic accuracy in
patients with advanced MTC as well as gastroenteropancreatic and bronchopulmonary NET. After
successful application in diagnostic imaging, CCK2R targeting with therapeutic radionuclides
bears high potential also to improve the therapeutic management of patients with advanced
disease.